Description

Date - 23rd Jun 2021

Indian pharmaceutical company Zydus Cadila is about to apply for a Drugs General Council of India (DGCI) approval for the emergency approval of the ZyCoV-D corona vaccine. If approved, it will be the world's first DNA-based vaccine. At the same time, the number of vaccines available in the country will increase to 4. At the moment, India uses the Serum Institute's Covishield, Bharat Biotech's Covaxin and Russia's Sputnik-V vaccines.

Single-dose or double dose

All three vaccines currently being administered in India are double doses. In the meantime, there are disposable vaccines such as Johnson & Johnson and Sputnik Lite that may hit India in the coming months. But the Zykov-D vaccine is different from all of these. Not one or two, but three doses of this Indian vaccine will be administered. During Phase 1 and Phase 2 trials, this vaccine retains immunity for a long time after three doses. However, Cadila is also testing two doses of the drug. Results related to this may also appear in the near future.

Vaccine administration method

ZyCoV-D is a needleless vaccine. It will be equipped with a jet injector. Jet nozzles are widely used in the United States and some other countries. This allows the vaccine to be injected under the human skin under high pressure. At the same time, with needle pricks, which are commonly used, fluid or medication will enter the muscles. Compressed gas or springs are used to pressurize the jet nozzles.

This device was invented in 1960. The WHO gave permission for its use in 2013. Jet injectors have been widely used in the United States since 2014. Along with this, they are also used in some countries in Europe, Africa and Asia.

Benefits of the Jet Vaccine

First, it reduces pain for the person receiving it because it does not penetrate your muscles like a regular injection. Secondly, the risk of spreading the infection is much less than that of a needle injection. Companies such as Farmjet, Spirit International, Valeritus Holdings, Injex, Enteris Pharma manufacture jet nozzles.

Vaccine Application Status

Cadila may apply to the DGCI for emergency ZyCoV-D approval this week. The analysis of the Phase 3 vaccine trial data is almost complete. The company reported this to the government. In addition to adults, this vaccine is also being tested on children between the ages of 12 and 18. This vaccine is also being tested in people already suffering from serious medical conditions. Zydus Cadila says it is producing 24 crore doses per year. The preparation of the company is such that it will enter the market in just a few days after receiving the approval. The company will produce 2 million vaccines every month. Along with this, negotiations are underway with other manufacturers to increase production. The company will produce about a million doses in the first month. After that, from next month, production will be doubled.

For more Updates and Information - Click here 

For access to more than 10,000 Colleges - Click here

For Latest Sarkari Jobs - Click here

For Comprehensive Preparation of Competitive Exams - Click here

For School Studies and Exams Preparation across Eight Boards - Click here